07:00 , Jun 9, 2016 |  BC Innovations  |  Strategy

Sanofi's post-reconstruction era

Lauren Martz, Senior Writer  Five years after taking the helm as Sanofi 's president of global R&D, Elias Zerhouni is rounding out his strategy to revamp the division and rebuild the pipeline with the appointment...
07:00 , Sep 17, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-221 (miR-221); miR-222

Cancer INDICATION: Multiple myeloma (MM) Mouse and patient sample studies suggest inhibiting miR-221 and miR-222 could help treat dexamethasone-resistant MM. Levels of miR-221 and miR-222 were higher in MM cells from patients with dexamethasone-resistant disease...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

Regulus preclinical data

In a mouse xenograft model of HCC, thrice-weekly subcutaneous 25 mg/kg anti-microRNA-221 (miR-221) oligonucleotides for 3 weeks significantly inhibited tumor growth vs. vehicle-treated controls (p<0.005). Data were presented at the American Association for Cancer Research...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

Regulus, Sanofi deal

Sanofi and Regulus extended a 2010 deal to discover, develop and commercialize microRNA therapeutics to treat Orphan indications and cancer. Under the extension, Regulus granted Sanofi an exclusive option to develop and commercialize Regulus' preclinical...
07:00 , Mar 14, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens MicroRNA detection with hairpin-mediated quadratic enzymatic amplification (HQEA) HQEA for miRNAs could enable sensitive detection of disease-associated miRNAs in clinical samples. The method involves...
07:00 , Jun 24, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Polyribonucleotide nucleotidyltransferase 1 (PNPT1; PNPASE) In vitro studies suggest that upregulating PNPASE could help treat cancer. In human melanoma cells, adenoviruses expressing PNPASE...
08:00 , Jan 14, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Liver cancer MicroRNA-221 (miR-221) In vitro and mouse studies suggest that inhibiting miR-221 could help treat liver cancer. An analysis of samples from hepatocellular carcinoma...
08:00 , Jan 7, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lung cancer; liver cancer MicroRNA-221 (miR-221); miR-222; phosphatase and tensin homolog deleted on chromosome ten (PTEN; MMAC1; TEP1); tissue inhibitor of metalloproteinases 3 (TIMP3); tumor...